|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Makucell Announces Key Scientific Findings for Its Proprietary Technology, Asymmtate™
7/17/2012 10:23:08 AM
SCOTTSDALE, Ariz. & LOS ANGELES--(BUSINESS WIRE)--Makucell, Inc., a pioneering regenerative biotechnology company dedicated to the development, manufacture and distribution of non-prescription products formulated to reduce the impact of aging on the skin’s appearance announces key scientific findings for its proprietary technology, Asymmtate™. Asymmtate™ is a cosmetic ingredient that influences the gene co-activator choice used by ß-catenin to encourage skin stem cell differentiation. The study’s results showed that application of a cream containing Asymmtate™ is associated with down-regulation of the gene expression of pro-opiomelanocortin (“POMC”) and up-regulation of melanocortin receptor (“MCR1”) in human skin compared to the base cream. Aging, especially photo-aging, causes differences in the distribution and activity of melanocytes leading to mottled pigmentation, freckles and lentigines (liver spots). The study results suggest that using a cream with Asymmtate™ may reverse gene expression changes associated with aging skin and with lentigines. Makucell’s Vice President and Chief Medical Officer, Mark V. Dahl, MD, will be presenting the poster at the Cosmetic Boot Camp in Colorado Springs, Colorado, which takes place July 19 through 21, 2012.
|
|
|
|
|
|
|
|
|
|
|